Lacidipine, a calcium channel blocker, exhibits significant anti-atherosclerotic effects in early vascular disease by preventing intimal thickening and improving vascular function. In a rabbit model of collar-induced atherosclerosis, lacidipine reduced pathological changes without the presence of hypercholesterolemia or hypertension. It normalized vascular reactivity, decreasing serotonin sensitivity and enhancing nitric oxide-mediated endothelium-dependent relaxation. Unlike traditional treatments focused on lipid metabolism, lacidipine’s effects were independent of changes in oxidant stress markers like nitrotyrosine or modulation of matrix metalloproteinase-9 (MMP-9). Its protective properties highlight its ability to target vascular remodeling directly through mechanisms associated with endothelial health and nitric oxide bioavailability, offering promise for managing atherosclerosis early.
Yetik, G., Üstünes, L., Dilsiz, O.Y., & Ergul, A. (2010) 'Lacidipine has anti-atherosclerotic effects independent of its actions on lipid metabolism and blood pressure', Vascular Pharmacology.
Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.
For more details consult with your doctor or healthcare professional.
Yetik, G., Üstünes, L., Dilsiz, O.Y., & Ergul, A. (2010) 'Lacidipine has anti-atherosclerotic effects independent of its actions on lipid metabolism and blood pressure', Vascular Pharmacology.
Yetik, G., Üstünes, L., Dilsiz, O.Y., & Ergul, A. (2010) 'Lacidipine has anti-atherosclerotic effects independent of its actions on lipid metabolism and blood pressure', Vascular Pharmacology.
Yetik, G., Üstünes, L., Dilsiz, O.Y., & Ergul, A. (2010) 'Lacidipine has anti-atherosclerotic effects independent of its actions on lipid metabolism and blood pressure', Vascular Pharmacology.